Part One: The Global BCI Landscape: A Nascent Market on the Eve of Transformation

Brain-Computer Interface (BCI) technology, the ultimate bridge connecting biological and machine intelligence, is rapidly transitioning from a science fiction concept to an industrial reality. The global BCI market is currently in a vibrant yet highly uncertain early stage, characterized by significant discrepancies in market size estimations, clear divergence in technological pathways, and a burgeoning exploration of application scenarios. Understanding this landscape is a prerequisite for analyzing any nation’s strategic intentions.

1.1 Scale and Opportunity: A Fragmented but Bullish Market

The assessment of the global BCI market size itself reveals the industry’s current state. Valuation data for 2024 shows vast differences, ranging from $262 million ¹, $1.6 billion ², $2.09 billion ³, to $2.3 billion.⁴ This wide divergence in valuation is not a simple statistical error but a direct reflection of a chaotic market definition. A narrow definition might only focus on the sales of core BCI hardware and software, a relatively small but tangible market. A broader definition, however, encompasses the entire ecosystem, including R&D funding, auxiliary devices, software services, and clinical trial expenditures.¹ For instance, one study breaks the market down into a massive $160.44 billion “Total Addressable Market” (TAM) for invasive BCIs and a mere $368.6 million “Serviceable Obtainable Market” (SOM) for non-invasive ones.⁵ This definitional chaos is a key signal that the market is still in its infancy, meaning that for investors, risk and opportunity coexist.

Despite the valuation differences, all reports are strikingly consistent in their future forecasts—the outlook is extremely positive. The compound annual growth rate (CAGR) for the forecast period is generally between 14.1% and 20.5%, with the market size expected to reach several times its current level by the end of this decade or the beginning of the next, with forecasts ranging from $506 million to $8.73 billion.¹

The core driver of market growth is the increasingly severe global health challenge. The rising prevalence of neurological diseases such as Parkinson’s, Alzheimer’s, amyotrophic lateral sclerosis (ALS), and stroke provides the most solid application base and ethical foundation for BCI technology.¹ Consequently, the healthcare sector currently holds the largest share of the BCI market, at 57.5%.⁵ Additionally, increased R&D investment, growing demand for non-invasive and wearable devices, and advances in artificial intelligence, machine learning, and sensor technology are also injecting strong momentum into the market.¹

However, significant obstacles remain on the path to widespread application. The high cost of BCI systems, including installation, maintenance, and specialized training, is the primary factor limiting their adoption.¹ At the same time, there is a severe shortage of professionals capable of operating these cutting-edge technologies ¹, and the strict, lengthy, and expensive regulatory approval processes, especially for implantable medical devices, greatly slow the pace of commercialization.⁶

Table 1: Comparison of Global BCI Market Size Forecasts (2024-2033)

Report Source	2024 Market Size (USD)	Forecast Market Size (USD) & Year	Compound Annual Growth Rate (CAGR)
MarketsandMarkets ¹	262 Million	506 Million (2029)	14.1%
Straits Research ³	2.09 Billion	8.73 Billion (2033)	15.13%
BCC Research ⁴	2.3 Billion	4.5 Billion (2029)	14.2%
World Economic Forum/SITE ⁷	1.74 Billion (2022)	6.2 Billion (2030)	17.5%
Market Research Intellect ²	1.6 Billion	6.3 Billion (2033)	20.5%

1.2 The Technology Nexus: From Scalp to Cortex

A fundamental dividing line exists in the BCI technology field: the degree of invasiveness, which determines the technology’s performance, risk, and application scope. The current market is primarily composed of three technological routes:

• Non-Invasive BCI: Mainly uses electroencephalography (EEG) technology, capturing brain signals via electrodes placed on the scalp. Due to its high safety, lower cost, and ease of use, non-invasive technology currently dominates market revenue.¹ It is the preferred technology for scientific research, consumer health products, and emerging consumer applications. Recent technological advances include the development of wearable EEG caps that incorporate machine learning to shorten training times ³ and the application of new sensing technologies like functional near-infrared spectroscopy (fNIRS).²

• Invasive BCI: Involves surgically implanting electrode arrays directly into or on the surface of the cerebral cortex, such as Blackrock Neurotech’s Utah Array and Neuralink’s “threads.” This type of technology offers unparalleled signal fidelity and functional restoration capabilities, making it the most well-funded and high-profile area of research, aimed at treating severe paralysis and serious neurological diseases.⁵

• Semi-Invasive/Endovascular BCI: An emerging route that lies between the two, represented by Synchron’s Stentrode™ technology. The device is implanted via the jugular vein and ultimately positioned in a blood vessel above the brain’s motor cortex, thus avoiding open-brain surgery while still obtaining high-quality brain signals.⁸ This method strikes a better balance between effectiveness and risk.

The current market presents a clear “hype versus revenue” paradox. Non-invasive technology contributes the vast majority of existing revenue ³, while invasive technology attracts the most venture capital, media attention, and is seen as the key to unlocking disruptive applications.⁸ This is not a contradiction but reflects two parallel innovation and investment cycles within the BCI field. In reality, the BCI industry can be seen as two separate markets operating on different timelines: one is a traditional med-tech/consumer electronics market, characterized by incremental innovation, existing revenue streams, and a focus on user experience and cost; the other is a venture capital-driven “moonshot” market, with minimal current revenue but extremely high valuations based on the huge potential for a “winner-takes-all” future. A key future trend may be the “trickle-down” application of advanced algorithms and AI developed for invasive systems to enhance the performance of cheaper, safer non-invasive devices.

1.3 The Main Battlegrounds: Mapping the Application Ecosystem

Healthcare is the undisputed “ballast” application area for BCI technology. Its applications are mainly focused on neuro-rehabilitation for stroke and spinal cord injury patients ², providing

assistive communication and control capabilities for paralyzed patients ³, and treating diseases such as

epilepsy and depression.⁵

However, BCI’s ambitions extend far beyond this, with several non-medical vertical sectors showing enormous growth potential:

• Entertainment & Gaming: With the rise of immersive technologies like virtual reality (VR) and augmented reality (AR), and the pursuit of new interactive experiences, this sector is predicted to see “lucrative growth”.²

• Defense & Military: Application scenarios include real-time monitoring of soldiers’ health and cognitive load, enhancing combat performance through neuromodulation techniques, and thought-based control of advanced drones and robots.²

• Consumer & Industrial: In the emerging consumer sector, BCI is being used for smart home control ¹, neuromarketing research, and improving industrial production safety.

Currently, the BCI industry is undergoing a fragmented development phase driven by application scenarios, actively searching for a “killer app” beyond the essential needs of healthcare. While restoring mobility to the paralyzed has immeasurable social value, making BCI a ubiquitous technology like the smartphone will depend on finding a sufficiently compelling consumer-grade application. Synchron’s integration of generative AI (like OpenAI’s technology) into its BCI platform ⁵ significantly lowers the barrier for users to perform complex tasks, which may be the key step in creating that “killer app” and driving BCI towards mass market adoption.

Part Two: The Future Builders: Competition and Strategic Dynamics

If Part One mapped the BCI industry’s landscape, Part Two focuses on the key forces shaping its future. This section will analyze the leading corporate players and compare the macro-strategic visions of major geopolitical powers, laying the groundwork for understanding China’s specific ambitions.

2.1 Pioneering Forces: An Overview of Global BCI Leaders

In the cutting-edge race of BCI, a few companies have distinguished themselves with unique technological paths and strong financial backing, becoming industry frontrunners.

• Neuralink: Founded by Elon Musk, its grand vision is to achieve a “symbiosis between the human brain and artificial intelligence”.⁸ Its core product, the
  N1 implant, contains 1024 electrodes distributed across 64 “threads” thinner than a human hair, implanted into the brain by a dedicated surgical robot.⁹ The company has raised over
  $1 billion in funding ⁸ and successfully performed its first human implant in January 2024, enabling a paralyzed patient to control a computer and play games using only their thoughts.⁹ Neuralink’s strategy is high-risk, high-reward, and technology-driven, aiming to eventually solve issues like blindness and depression, and to achieve cognitive enhancement.⁹

• Synchron: This company has pioneered a less invasive endovascular BCI technology. Its Stentrode™ device is implanted via the jugular vein, avoiding open-brain surgery.⁸ Backed by strategic investors like Jeff Bezos and Bill Gates, Synchron has raised
  $145 million ⁸ and is highly focused on safety and a pragmatic regulatory path. It was the first company to receive FDA approval for human trials of a permanently implanted BCI and has successfully enabled paralyzed patients to send texts, emails, and even use generative AI.⁵

• Blackrock Neurotech: As an industry veteran, Blackrock Neurotech has established a strong position in academia and clinical research with its renowned Utah Array.⁸ The company has over 19 years of experience in human studies, and its technology has been adopted by more than 1,000 research institutions worldwide.¹⁴ Its
  MoveAgain BCI system has received FDA “Breakthrough Device” designation, aiming to be the first implantable BCI system for home use by patients with tetraplegia to restore their communication and motor functions.⁸

Table 2: Overview of Major Global BCI Companies

Company	Technology/Path	Core Product	Key Differentiator	Total Funding	Clinical/Regulatory Status
Neuralink	Invasive - Intracortical	N1 Implant	Ultra-high channel count, robotic surgery, AI symbiosis vision	> $1 Billion	First human implant completed in 2024 ⁸
Synchron	Invasive - Endovascular	Stentrode™	Avoids open-brain surgery, higher safety profile	$145 Million	First to receive FDA approval for permanent implant human trials ⁸
Blackrock Neurotech	Invasive - Intracortical	Utah Array / MoveAgain System	Long-term clinical validation, academic standard, focus on medical applications	> $200 Million	MoveAgain received FDA “Breakthrough Device” designation ⁸

2.2 Grand Strategies: The Tale of Three Initiatives (U.S., EU, and China)

Globally, it is not just companies but also grand national strategies that are driving BCI development. The different strategic paths of the United States, the European Union, and China reveal their distinct philosophical approaches to this disruptive technology’s future.

• The U.S. BRAIN Initiative: Launched in 2013, its core objective is to understand brain function by accelerating the development of innovative neurotechnologies, as its full name, “Brain Research Through Advancing Innovative Neurotechnologies,” suggests.¹⁵ This is a “tool-builder’s” project, focused on funding basic science research, creating new methods for mapping and modulating neural circuits, and fostering interdisciplinary collaboration.¹⁵ Its success is measured by scientific breakthroughs, such as high-resolution brain mapping and advanced deep brain stimulation (DBS) techniques for treating Parkinson’s disease.¹⁷ Its emphasis is on “enabling discovery.”

• The EU’s Human Brain Project (HBP): This ten-year, €1 billion project (2013-2023) had the central goal of building a unified, ICT-based research infrastructure, which is now the EBRAINS platform.¹⁸ This was an “integrator’s” project, aiming to use supercomputing, simulation, and data platforms to create multi-scale models of the brain and to integrate Europe’s fragmented neuroscience research.²¹ Its main legacy is the EBRAINS platform, intended to be a lasting research resource for the global scientific community.²²

• China’s National Strategy: As will be detailed in Part Three, China’s path is distinctly different. It is an “industrialist’s” project, explicitly aimed at building a sovereign, globally competitive BCI industry.²³ While it includes basic research, its overwhelming focus is on applied R&D, commercialization, and achieving specific industrial targets.

These three distinct strategic philosophies are not simply competing in the same race; they are running on the same track with different finish lines. The U.S. is focused on creating the foundational intellectual property and scientific knowledge (“what is it?”); the EU is focused on building collaborative platforms to analyze and share that knowledge (“how to do it?”); and China is focused on turning that knowledge into products and market share (“what is it for?”). This divergence heralds a new, complex phase of global “coopetition.” Chinese industry will seek to license or acquire core technologies developed in the U.S., while American and European researchers will want to leverage China’s growing datasets and manufacturing scale. However, the explicit goal of industrial supremacy in China’s policy ²⁵ and U.S. export control concerns ²⁴ will inevitably create friction. This sets the stage for a future BCI world that is multipolar, with different centers of gravity.

Part Three: Decoding Beijing’s Ambition: Analyzing the ‘Guiding Opinions’

This section is the core of the report, providing an in-depth analysis of China’s official BCI industry policy—the “Guiding Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry,” jointly issued by seven government departments, including the Ministry of Industry and Information Technology. The report will deconstruct the policy’s goals and tasks, analyze the domestic players it empowers, and assess its strategic impact on the global order.

3.1 A Blueprint for Supremacy: Deconstructing the Policy Goals

The “Guiding Opinions,” jointly issued by seven ministries, set clear, time-bound, and ambitious goals for the development of China’s BCI industry. Its wording and highly specific targets amount to nothing less than a “battle plan” for industrial development.²⁵

• By 2027: Achieve breakthroughs in key technologies; preliminarily establish advanced systems for technology, industry, and standards; ensure that the performance of electrodes, chips, and complete systems reaches “international advanced levels”; accelerate applications in industrial manufacturing, healthcare, and consumer life; and build 2 to 3 industrial development clusters.²⁵

• By 2030: “Significantly enhance” the industry’s innovation capabilities; form a “safe and reliable” industrial system; cultivate 2 to 3 globally influential leading enterprises and a batch of “specialized, refined, distinctive, and new” small and medium-sized enterprises; and ultimately achieve “comprehensive strength ranking among the world’s forefront”.²⁵

These goals are not just an R&D funding program but a comprehensive industrial strategy aimed at achieving technological sovereignty and economic power. The language is that of a contender for leadership, not a participant. Phrases like “world’s forefront” and “globally influential leading enterprises” directly state the intention to challenge the current U.S. dominance in the field. This policy is the culmination of years of planning, with “Brain Science and Brain-Like Research” previously listed as a major science and technology project in the “13th Five-Year Plan” ³¹ and BCI regarded as a “new quality productive force” driving economic development.²⁴ This sends a clear signal to domestic companies that they will have state support in global competition, and a warning to international firms that China intends to cultivate its own champions, not just be a market for foreign products.

Table 3: Key Goals and Timetable of China’s BCI ‘Guiding Opinions’

Development Stage	Specific Goals
By 2027 (Short-term Goals)	- Achieve breakthroughs in key technologies, preliminarily establishing systems for technology, industry, and standards. - Performance of electrodes, chips, and complete systems to reach international advanced levels. - Accelerate applications in industry, healthcare, and consumer sectors, opening up new scenarios and models. - Build 2 to 3 industrial development clusters, with continuous growth in industrial scale.
By 2030 (Long-term Goals)	- Significantly enhance industrial innovation capability, with comprehensive strength entering the world’s forefront. - Form a safe and reliable industrial system, building an internationally competitive industrial ecosystem. - Cultivate 2 to 3 globally influential leading enterprises. - Nurture a batch of “specialized, refined, distinctive, and new” SMEs.

²⁵

3.2 The Engine Room: Key Tasks and Priority Areas

The “Guiding Opinions” outline a “full-stack” development path aimed at controlling the entire value chain, from underlying core technologies to the upper-level application ecosystem.²⁵

• Core Hardware and Software R&D:

  • Hardware: At the sensing element level, it calls for innovative R&D of implantable electrodes (epidural/subdural, intracortical), exploration of endovascular electrodes, and improvement of material stability and biocompatibility. At the core chip level, it demands breakthroughs in high-channel acquisition chips, ultra-low-power processing chips, and high-speed communication chips.

  • Software: At the software tool level, it requires strengthening the software foundation, improving encoding/decoding software (using AI to enhance performance), developing dedicated control software, and specifically emphasizing the construction of a “dedicated operating system and a universal software platform.”

• High-Performance Product Development: Accelerate R&D breakthroughs for implantable devices while promoting mass production and iteration of non-invasive devices.

• Ecosystem Construction: Promote the application of technological achievements, build testing and pilot production platforms, cultivate leading enterprises, promote industrial clustering, and strengthen standards leadership, security assurance, and talent cultivation.

To achieve these tasks, the policy explicitly states that national-level funds (such as the National Manufacturing Transformation and Upgrading Fund) will be used for investment, financial tools like “technology-industry-finance integration” will be utilized, and approval support will be provided for implantable BCI medical devices.²⁸

This list of tasks reveals a highly mature strategic thinking. The focus is not just on manufacturing devices, but on controlling the entire technology stack. The explicit call to establish a “dedicated operating system” is particularly crucial. In the tech world, the owner of the platform (like Google’s Android or Microsoft’s Windows) controls the ecosystem and captures the most value. This indicates that China is applying lessons learned from fierce competition in semiconductors and smartphones to the BCI field. The goal is to build a self-sufficient BCI industry that can withstand foreign sanctions or export controls.²⁴ By controlling core components (chips, electrodes) and core platforms (operating systems), China aims to create a parallel BCI ecosystem that it can dominate and export to its global geopolitical partners, such as those in the “Belt and Road” initiative. This is a long-term strategy focused on supply chain resilience and technological dominance.

3.3 China’s Emerging Champions: The Domestic Industrial Base

China’s BCI industrial ecosystem is rapidly maturing, laying a solid foundation to undertake the ambitious goals of the national strategy. It is estimated that the Chinese BCI market size reached 3.2 billion RMB (approx. $440 million) in 2024 and is expected to grow to 5.58 billion RMB (approx. $770 million) by 2027.³¹

• Leading Companies:

  • StairMed: Has become a frontrunner in the invasive track, with its Series B financing reaching 350 million RMB (approx. $48 million), a record for the domestic field. The company focuses on high-throughput implantable systems and has conducted over 50 clinical studies in collaboration with top hospitals.³²

  • Other Key Players: Include BrainCo, a leader in non-invasive smart prosthetics; Neuro-X, which has made breakthroughs in invasive language decoding; and Boocaxle, which is developing semi-invasive systems in collaboration with Tsinghua University.³¹

• Research Powerhouses:

  • Tsinghua University: A global leader in BCI research, its team developed the NEO, a wireless, minimally invasive, semi-invasive system that has successfully enabled a high-level paraplegic patient to autonomously grasp a water bottle to drink.³⁴

  • Other Academic Forces: Fudan University has launched a $56 million BCI research center in Shanghai ³, while
    Zhejiang University completed China’s first implantable BCI clinical study in 2020.³⁵

These companies and research institutions form the solid base of China’s BCI industry and are likely to be the primary recipients of the state support and resources mentioned in the “Guiding Opinions.”

Table 4: Overview of Major Chinese BCI Companies and Research Institutions

Entity Name	Type	Technology Focus	Core Product/Achievement	Latest Funding/Milestone
StairMed	Company	Invasive	High-throughput implantable BCI system	Received 350M RMB Series B funding, conducted >50 clinical studies ³²
BrainCo	Company	Non-invasive	Smart bionic hand (FDA certified)	Completed ~$300M financing for R&D ³¹
Neuro-X	Company	Invasive	Breakthrough in language decoding clinical trials	Continuing R&D on high-channel electrophysiology recording systems ³³
Boocaxle	Company	Semi-invasive	Co-developed NEO system with Tsinghua University	Completed 5 funding rounds up to Series D since 2018 ³³
Tsinghua University	University	Semi-invasive/Non-invasive	NEO wireless minimally invasive system, high-speed BCI system	NEO system enabled paralyzed patient to autonomously grasp and drink ³⁶
Fudan University	University	Invasive/Comprehensive	-	Launched a $56 million BCI research center ³

3.4 Strategic Implications: A New Center of Gravity?

China’s “Guiding Opinions” must be interpreted within a broader geopolitical context. The United States has already placed BCI technology on its export control list for China ²⁴, and China’s strategy is precisely aimed at achieving self-sufficiency and countering these restrictions. Furthermore, BCI technology has significant national security implications, with nations exploring its military applications (“neuro-warfare,” “super-soldiers”) ¹³, while concerns about the use of neural data for state surveillance (“data-driven authoritarianism”) are also growing.²³

The combination of U.S. technology export controls and China’s state-driven, full-stack industrial self-sufficiency strategy will almost inevitably lead to a “bifurcation” of the global BCI market. The future may see the formation of two relatively independent camps: one centered on U.S. technology and standards, in alliance with its close partners (like Europe and Japan); the other centered on China’s technology stack, exported through initiatives like the “Belt and Road.”

For global companies and investors, this will create immense strategic complexity. They will have to choose between two ecosystems. Supply chains will diverge, data privacy and security standards will differ greatly, and interoperability will become a major challenge. China’s “Guiding Opinions” have drawn a clear line in the sand for this future battlefront.

Part Four: Navigating the Labyrinth: Ethics, Risks, and the Path to Commercialization

The greatest obstacle on BCI technology’s path to the future may not be the technology itself, but the profound ethical, legal, and social issues it raises. Successfully navigating this “minefield” is no longer a secondary consideration but a core competency that will determine success or failure.

4.1 Ghost in the Machine: Defusing the Ethical Minefield

The development of BCI has triggered unprecedented ethical challenges, which have become a focus of intense debate in academia and the public sphere.⁴¹

• Privacy & Data Security: BCI could directly access an individual’s most private data—their thoughts and intentions. Concerns about “brain tapping” ⁷, data ownership, and data misuse are paramount.⁴²

• Autonomy & Agency: The possibility of a BCI being “hijacked” to compel a user’s actions ⁷, or a bidirectional interface influencing a user’s thoughts and self-perception ⁴², raises deep concerns about free will.

• Psychological Impact: Studies show that invasive BCIs can cause significant psychological distress for users, challenging their sense of identity.⁴⁴ Furthermore, the dashing of unrealistic patient expectations can also cause severe psychological harm.⁴⁵

• Equity & Justice: The high cost of advanced BCI technology could create a “digital divide” world of enhanced “superhumans” and ordinary people, exacerbating social inequality.⁴⁶

• The Line Between Therapy & Enhancement: The boundary between restoring function and enhancing normal human capabilities is becoming increasingly blurred, which is ethically highly contentious.⁴⁴ It is noteworthy that the ethical guidelines released by China also explicitly recognize this and call for stricter controls on enhancement applications.⁴⁷

These Ethical, Legal, and Social Implications (ELSI) are not abstract debates; they are direct threats to commercialization. Public mistrust could lead to devastating regulatory policies. Therefore, the race to develop BCI technology is, in a sense, also a race to establish a credible and viable governance framework. The nation or region that can first create a clear, efficient, and ethically sound regulatory pathway—a framework of “Neuro-Rights”—will gain a significant competitive advantage. This will provide legal certainty for companies, build public trust, and attract top talent and investment. China’s proactive release of national-level BCI ethical guidelines ⁴⁷, though it may be viewed with skepticism in the West, is undoubtedly a strategic move to demonstrate leadership in this critical area and to attempt to shape future global norms. The ethical debate is no longer a sideshow; it is the central battlefield of the global BCI competition.

4.2 Strategic Synthesis and Forward-Looking Recommendations

Strategic Synthesis

The global BCI industry is at a critical inflection point. It is defined by three major divides: a technological split between non-invasive and invasive technologies, a market split between near-term medical applications and long-term consumer visions, and a geopolitical split between different national strategies. The U.S. currently leads in basic R&D and high-profile innovation, but China’s “Guiding Opinions” represent the most comprehensive and aggressive industrial policy in the field to date. This document is a clear blueprint for China’s ambition to achieve technological sovereignty and global leadership, setting the stage for a future of bipolarity and intense competition in the global market.

Forward-Looking Recommendations

The ultimate trajectory of the BCI industry will depend not only on technological breakthroughs but also on whether stakeholders can successfully navigate the profound ethical labyrinth and win public trust. The next decade will witness a fierce race—not just to build the most powerful BCI, but to write the rules that will govern it.

• For Investors:

  • Acknowledge the reality of a “bifurcated market” and diversify investments between the stable, regulated medical market and the high-risk, high-reward invasive/enhancement market.

  • When evaluating a company, place as much importance on its regulatory and ethical strategy as on the technology itself.

• For Western Policymakers:

  • Recognize China’s policy as a strategic challenge. Accelerate the development of clear and efficient domestic regulatory and ethical frameworks to maintain a competitive edge.

  • De-risk the long development cycle of invasive BCIs through public-private partnership models to encourage innovation.

• For Industry Players:

  • Form strategic alliances to navigate the increasingly divided global market.

  • Invest heavily in “security-by-design” for safety and privacy to build user trust.

  • Proactively engage in shaping ethical standards rather than passively waiting for regulation to arrive.

Cited works

1. Brain Computer Interface Market Growth, Drivers, and Opportunities - MarketsandMarkets, https://www.marketsandmarkets.com/Market-Reports/brain-computer-interface-market-64821525.html

2. Brain Computer Interface Market to Soar from USD 1.6 Billion in 2024 to USD 6.3 Billion by 2033, at 20.5% CAGR - Market Research Intellect, https://www.prnewswire.com/news-releases/brain-computer-interface-market-to-soar-from-usd-1-6-billion-in-2024-to-usd-6-3-billion-by-2033--at-20-5-cagr---market-research-intellect-302524372.html

3. Brain Computer Interfaces Market Size, Trends & Growth Graph by …, https://straitsresearch.com/report/brain-computer-interfaces-market

4. Global Brain-Computer Interface Market Size & Growth Report - BCC Research, https://www.bccresearch.com/market-research/instrumentation-and-sensors/brain-computer-interface-market.html

5. Brain Computer Interface Market Size | Industry Report, 2030 - Grand View Research, https://www.grandviewresearch.com/industry-analysis/brain-computer-interfaces-market

6. Challenges and advances in brain-computer interfaces, https://medicalethicshealthpolicy.med.upenn.edu/in-the-news/challenges-and-advances-in-brain-computer-interfaces

7. The brain computer interface market is growing – but what are the risks?, https://www.weforum.org/stories/2024/06/the-brain-computer-interface-market-is-growing-but-what-are-the-risks/

8. 9 Leading Brain-Computer Interface Companies and their Current …, https://rossdawson.com/futurist/companies-creating-future/leading-brain-computer-interface-companies-bci/

9. Neuralink: The Company Accelerating Human Potential - Technology Magazine, https://technologymagazine.com/articles/neuralink-the-company-accelerating-human-potential

10. Top 10 Brain-Computer Interface Companies in 2025 - Spherical Insights, https://www.sphericalinsights.com/blogs/top-10-companies-leading-the-brain-computer-interface-market-in-2025-key-players-statistics-future-trends-2024-2035

11. Neuralink’s Ambitious Journey Towards Brain-Computer Interfaces: An Analysis - MarketsandMarkets, https://www.marketsandmarkets.com/industry-news/Neuralinks-Ambitious-Journey-Towards-Brain-Computer-Interfaces

12. 2021年中国脑机接口平台行业概览, https://pdf.dfcfw.com/pdf/H3_AP202201121539917091_1.pdf?1641976029000.pdf

13. 脑机接口的军事前景-瞭望周刊社, https://lw.xinhuanet.com/20241021/8a1493f85c7249819ea1299c747f7bd2/c.html

14. Blackrock Neurotech | Empowered by Thought, https://blackrockneurotech.com/

15. BRAIN 2025: A Scientific Vision | BRAIN Initiative, https://braininitiative.nih.gov/vision/nih-brain-initiative-reports/brain-2025-scientific-vision

16. The State of the NIH BRAIN Initiative - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC6052245/

17. A look back on the BRAIN Initiative in 2024 (and what’s coming in 2025!), https://www.braininitiative.org/achievements/a-look-back-on-the-brain-initiative-in-2024-and-whats-coming-in-2025/

18. en.wikipedia.org, https://en.wikipedia.org/wiki/Human_Brain_Project#:~:text=The%20primary%20objective%20of%20the,is%20divided%20into%2012%20Subprojects.

19. Human Brain Project - Wikipedia, https://en.wikipedia.org/wiki/Human_Brain_Project

20. Human Brain Project - EBRAINS, https://files.ebrains.eu/file/b8c49d66-ce42-4405-b8dc-88105e35d784/hbp-10-year-assessment.pdf

21. The Human Brain Project—Synergy between neuroscience …, https://pmc.ncbi.nlm.nih.gov/articles/PMC6625714/

22. Overview - Human Brain Project, https://www.humanbrainproject.eu/en/about/overview/

23. Neurotechnology and international security | Politics and the Life Sciences | Cambridge Core, https://www.cambridge.org/core/journals/politics-and-the-life-sciences/article/neurotechnology-and-international-security/29155A74DBB0FDE5CB0CBA4D3DF6AF0C

24. 【理响中国】脑机接口加速形成新质生产力的理与路, https://www.cssn.cn/skgz/bwyc/202403/t20240327_5742356.shtml

25. 七部门关于推动脑机接口产业创新发展的实施意见_国务院部门文件_ …, https://www.gov.cn/zhengce/zhengceku/202508/content_7035603.htm

26. 到2027年脑机接口关键技术取得突破 - 中安在线, http://news.anhuinews.com/xwgn/202508/t20250808_8694649.html

27. 数据宝 - 证券时报官方网站-中国资本市场信息披露平台, https://www.stcn.com/article/wx/sjb.html

28. 七部门：到2027年脑机接口关键技术取得突破 - 数字中国建设峰会, https://www.szzg.gov.cn/2025/xwzx/szkx/202508/t20250808_5059132.htm

29. 图表：七部门：到2027年脑机接口关键技术取得突破 - 中国政府网, https://www.gov.cn/zhengce/jiedu/tujie/202508/content_7035617.htm

30. 七部门：到2027年脑机接口关键技术取得突破初步建立先进的技术体系 - 财联社, https://www.cls.cn/detail/2108770

31. 政策持续加码脑机接口发展前景广阔 - 证券时报, https://stcn.com/article/detail/1567817.html

32. 中国植入式脑机接口获3.5亿元最大融资：脑机接口，风口已至？ - 21 …, https://m.21jingji.com/article/20250212/herald/574c9e566084221e3394defdc27441a6.html

33. 多路线齐头并进脑机接口产业化进程加速-新华网, http://www.news.cn/fortune/20250526/017cb6b1c00047deb5f8944634f384c0/c.html

34. 国内脑机接口商业化至少仍需2年，百亿市场还有哪些挑战 - 清华大学, https://www.tsinghua.edu.cn/info/1182/109897.htm

35. 天风医药产业前沿专题系列研究脑机接口产业, https://pdf.dfcfw.com/pdf/H301_AP202404011629191867_1.pdf

36. 脑机接口技术革命：从瘫痪者重获新生到“脑控”未来 - 中国网, http://www.china.com.cn/txt/2025-05/16/content_117878997.shtml

37. 中国脑机接口行业发展模式及未来展望, http://lib.ia.ac.cn:8003/ContentDelivery/20220901/2022%E5%B9%B4%20%20%E3%80%9036%E9%A1%B5%E3%80%91%E4%B8%AD%E5%9B%BD%E8%84%91%E6%9C%BA%E6%8E%A5%E5%8F%A3%E8%A1%8C%E4%B8%9A%E5%8F%91%E5%B1%95%E6%A8%A1%E5%BC%8F%E5%8F%8A%E6%9C%AA%E6%9D%A5%E5%B1%95%E6%9C%9B_BA75431F0B52A5E23D89206A24DE8677.pdf

38. 未来产业｜国产脑机接口开年揽金前三个月融资达去年2.67倍 - 新京报, https://m.bjnews.com.cn/detail/1742298906129775.html

39. 高小榕 - 清华大学医学院, https://www.med.tsinghua.edu.cn/info/1142/2105.htm

40. Data-Centric Authoritarianism: How China’s Development of Frontier Technologies Could Globalize Repression - NATIONAL ENDOWMENT FOR DEMOCRACY, https://www.ned.org/data-centric-authoritarianism-how-chinas-development-of-frontier-technologies-could-globalize-repression-2/

41. Media Representation of the Ethical Issues Pertaining to Brain–Computer Interface (BCI) Technology - MDPI, https://www.mdpi.com/2076-3425/14/12/1255

42. Ethical and Social Challenges of Brain-Computer Interfaces - AMA Journal of Ethics, https://journalofethics.ama-assn.org/article/ethical-and-social-challenges-brain-computer-interfaces/2007-02

43. Brain-Computer Interfaces: Applications, Challenges, and Policy Options | U.S. GAO, https://www.gao.gov/products/gao-25-106952

44. Studies Outline Key Ethical Questions Surrounding Brain-Computer Interface Tech, https://news.ncsu.edu/2020/11/brain-computer-interface-ethics/

45. Ethical issues with brain-computer interfaces - Frontiers, https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2014.00136/full

46. Ethical considerations for the use of brain–computer interfaces for cognitive enhancement, https://pmc.ncbi.nlm.nih.gov/articles/PMC11542783/

47. China’s new ethical guidelines for the use of brain–computer interfaces - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11085839/